Facing the Challenges in Vaccine Upstream Bioprocessing - 8

Facing the Challenges in Vaccine Upstream Bioprocessing * Interview: Vaccine Manufacturing

GEN: Economic considerations are an important
factor in vaccine development. Which strategies
for cost reduction can you envision to motivate
the development of new vaccines to so-far overlooked diseases?
Mr. Khambati: Strategies for making vaccine
manufacturing cost effective and viable have
always been a big challenge for companies
engaged in this business. The application
of manufacturing strategies like continous
processing, low footprint plant with low utility
demands, better process control, and reduced failures can substantially improve the bottom lines.
A number of manufacturers are also exploring the
possibility of developing mixture vaccines (e.g.,
pentavalent or hexavalent) as therapies against
multiple life-threatening diseases. Thus, reducing
the number of dosing events and improving the
manufacturing logistics are important economic
considerations.

8

| GENengnews.com

Dr. Lovrecz: Single-use flexible bioreactors
using suspension cell lines, better immunogenicity, improved cell lines, higher final density
and, perhaps, novel platforms should enable the
development of new vaccines especially for the
developing world and for overlooked diseases.
The Coalition for Epidemic Preparedness Innovations (CEPI) and similar initiatives are reassuring. n



http://www.GENengnews.com

Facing the Challenges in Vaccine Upstream Bioprocessing

Table of Contents for the Digital Edition of Facing the Challenges in Vaccine Upstream Bioprocessing

Contents
Facing the Challenges in Vaccine Upstream Bioprocessing - 1
Facing the Challenges in Vaccine Upstream Bioprocessing - 2
Facing the Challenges in Vaccine Upstream Bioprocessing - 3
Facing the Challenges in Vaccine Upstream Bioprocessing - Contents
Facing the Challenges in Vaccine Upstream Bioprocessing - 5
Facing the Challenges in Vaccine Upstream Bioprocessing - 6
Facing the Challenges in Vaccine Upstream Bioprocessing - 7
Facing the Challenges in Vaccine Upstream Bioprocessing - 8
Facing the Challenges in Vaccine Upstream Bioprocessing - 9
Facing the Challenges in Vaccine Upstream Bioprocessing - 10
Facing the Challenges in Vaccine Upstream Bioprocessing - 11
Facing the Challenges in Vaccine Upstream Bioprocessing - 12
Facing the Challenges in Vaccine Upstream Bioprocessing - 13
Facing the Challenges in Vaccine Upstream Bioprocessing - 14
Facing the Challenges in Vaccine Upstream Bioprocessing - 15
Facing the Challenges in Vaccine Upstream Bioprocessing - 16
Facing the Challenges in Vaccine Upstream Bioprocessing - 17
Facing the Challenges in Vaccine Upstream Bioprocessing - 18
Facing the Challenges in Vaccine Upstream Bioprocessing - 19
Facing the Challenges in Vaccine Upstream Bioprocessing - 20
Facing the Challenges in Vaccine Upstream Bioprocessing - 21
Facing the Challenges in Vaccine Upstream Bioprocessing - 22
Facing the Challenges in Vaccine Upstream Bioprocessing - 23
Facing the Challenges in Vaccine Upstream Bioprocessing - 24
Facing the Challenges in Vaccine Upstream Bioprocessing - 25
Facing the Challenges in Vaccine Upstream Bioprocessing - 26
Facing the Challenges in Vaccine Upstream Bioprocessing - 27
Facing the Challenges in Vaccine Upstream Bioprocessing - 28
Facing the Challenges in Vaccine Upstream Bioprocessing - 29
Facing the Challenges in Vaccine Upstream Bioprocessing - 30
Facing the Challenges in Vaccine Upstream Bioprocessing - 31
Facing the Challenges in Vaccine Upstream Bioprocessing - 32
Facing the Challenges in Vaccine Upstream Bioprocessing - 33
Facing the Challenges in Vaccine Upstream Bioprocessing - 34
Facing the Challenges in Vaccine Upstream Bioprocessing - 35
https://www.nxtbookmedia.com